Dated June 22nd, RVX is the last of the 3 mentioned:

https://www.fool.ca/2018/06/22/young-investors-3-biotech-stocks-that-can-electrify-your-tfsa/

According to a 2017 report from Grand View Research, the global biotechnology market is projected to be worth $727.1 billion by 2025. This represents a compound annual growth rate (CAGR) of 7.4%. The potential of the biotech market should be a major point of attention, particularly for young investors.

Today we’ll look at three stocks in this market. Should you scoop up any or all of these stocks today? Let’s dive in.

Resverlogix Corp. (TSX:RVX)

Resverlogix is a Calgary-based clinical stage cardiovascular company. It is currently developing RVX-208, a small molecule used for the treatment of atherosclerosis. Atherosclerosis is a disease in which plaque builds up inside the arteries.

On June 14 Resverlogix announced that it had received confirmation from the U.S. Food and Drug Administration that BETonMACE would likely find support for the filing of an approval of a New Drug Application if the Phase 3 study is successful.

There is promise here, but also a gamble on the commercial success or failure of its products.